Ok so it looks like there is a lot of confusion on this remdesivir news. Here is a lay person summary.
There are numerous on going trials on remdesivir. Gilead, the manufacturer has 2- one in severe patients getting either 5 or 10 days, one in moderate patients w control arm.
There are numerous on going trials on remdesivir. Gilead, the manufacturer has 2- one in severe patients getting either 5 or 10 days, one in moderate patients w control arm.
In addition, there is a Chinese study in sicker patients (data pending).
And NIAID study in hospitalized patients with control arm.
And a WHO/INSERM study
gilead.com/purpose/advanc…
And NIAID study in hospitalized patients with control arm.
And a WHO/INSERM study
gilead.com/purpose/advanc…
Today, Gilead released data on its trial w sick patients (no control) that showed outcomes same in 5 and 10 da. Gilead also preempted NIAID saying that the NIAID study (with control arm) met its primary outcome: time to recovery.
NIAID has now announced it will release information about its trial at coronavirus briefing TODAY.
All together, today’s news: watch to check if NIAID confirms positive results. If true, Gilead trial tells us 5 & 10 d courses both good- so drug supply goes twice as far
All together, today’s news: watch to check if NIAID confirms positive results. If true, Gilead trial tells us 5 & 10 d courses both good- so drug supply goes twice as far
We have prior abstract that was released about the Chinese study with sicker patients that supposedly showed no mortality benefit but no one has yet seen the study. We need to look at results of this study when published as well.
We additionally need to watch for results from Gileads study of moderately ill patients.
Re General use of antiviral medications that block replication (like remdesivir) in viral illnesses. Antivirals work better if given earlier in disease. We need to look at overall mortality benefit but also whether giving at a time point sooner in disease makes difference
Also Chinese study just published but as @chungk1031 mentions- it’s underpowered as enrollment ended early due to drop in cases thelancet.com/journals/lance…
So original plan for this published study was sample size of 325 across both groups to meet 80% power to detect difference in hazard ratio. They ended up with only 237 so it’s underpowered but also interesting:
NOT statistically significant but trend towards “patients receiving remdesivir or placebo within 10 days of symptom onset in the ITT population, those receiving remdesivir had a numerically faster time to clinical improvement than those receiving placebo”
Lastly this tweet about Dr Fauci on results of NIAId results. Seriously! We need to just need the results released.
Here is NIAID's press release: niaid.nih.gov/news-events/ni…
